Profile data is unavailable for this security.
About the company
Nuvation Bio Inc. is a biopharmaceutical company. The Company is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. The Company is advancing multiple clinical-stage candidates, including a ROS1 inhibitor, a mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor, a bromodomain and extra-terminal (BET) inhibitor, and a drug-drug conjugate (DDC). Its portfolio of development candidates includes taletrectinib (ROS1), safusidenib (mIDH1), NUV-868 (BET), and NUV-1511 (DDC). Taletrectinib is an oral, potent, CNS-active, selective, ROS1 inhibitor specifically designed for the potential treatment of ROS1-positive non-small cell lung cancer (NSCLC). Safusidenib is an oral, potent, targeted inhibitor of mIDH1 being evaluated in a global Phase II trial in patients with low-grade IDH1-mutant glioma. NUV-868 is a BD2-selective oral small molecule BET inhibitor, that inhibits BRD4. It is conducting Phase I/II study of NUV-1511.
- Revenue in USD (TTM)1.44m
- Net income in USD-510.72m
- Incorporated2020
- Employees167.00
- LocationNuvation Bio Inc357 Tehama Street, Floor 3SAN FRANCISCO 94103United StatesUSA
- Phone+1 (415) 754-3517
- Fax+1 (302) 636-5454
- Websitehttps://www.nuvationbio.com/
Mergers & acquisitions
Acquired company | NUVB:NYQ since announced | Transaction value |
---|---|---|
AnHeart Therapeutics Inc | 21.21% | 100.69m |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Terns Pharmaceuticals Inc | 0.00 | -95.90m | 845.68m | 66.00 | -- | 3.22 | -- | -- | -1.31 | -1.31 | 0.00 | 3.11 | 0.00 | -- | -- | 0.00 | -36.84 | -41.34 | -38.72 | -45.70 | -- | -- | -- | -31,010.30 | -- | -- | 0.00 | -- | -- | -- | -49.49 | -- | -26.60 | -- |
Silence Therapeutics plc | 23.85m | -53.42m | 852.48m | 115.00 | -- | 6.18 | -- | 35.75 | -0.4294 | -0.4294 | 0.1905 | 1.07 | 0.1273 | -- | 2.56 | 207,357.10 | -28.51 | -43.60 | -32.89 | -54.91 | 56.40 | -- | -224.01 | -287.30 | -- | -- | 0.0016 | -- | 44.99 | -- | -6.86 | -- | 156.10 | -- |
89bio Inc | 0.00 | -174.61m | 867.40m | 70.00 | -- | 1.67 | -- | -- | -1.97 | -1.97 | 0.00 | 4.91 | 0.00 | -- | -- | 0.00 | -32.50 | -45.50 | -34.68 | -49.31 | -- | -- | -- | -- | -- | -- | 0.0465 | -- | -- | -- | -39.37 | -- | -36.58 | -- |
Oruka Therapeutics Inc | 0.00 | -7.20m | 874.96m | 4.00 | -- | 0.9278 | -- | -- | -5.97 | -5.97 | 0.00 | 26.94 | 0.00 | -- | -- | 0.00 | -19.22 | -27.78 | -19.99 | -29.38 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 46.21 | -- | -- | -- |
Applied Therapeutics Inc | -333.00k | -161.09m | 884.32m | 31.00 | -- | 12.22 | -- | -- | -1.52 | -1.52 | -0.0029 | 0.6303 | -0.0039 | -- | -- | -13,320.00 | -187.94 | -140.37 | -467.74 | -240.93 | -- | -- | -- | -4,476.42 | -- | -- | 0.00 | -- | -- | -- | -45.15 | -- | -- | -- |
Tango Therapeutics Inc | 42.51m | -116.49m | 889.30m | 140.00 | -- | 3.59 | -- | 20.92 | -1.11 | -1.11 | 0.4068 | 2.31 | 0.1118 | -- | -- | 303,635.70 | -30.62 | -- | -35.13 | -- | -- | -- | -274.04 | -- | -- | -- | 0.00 | -- | 46.93 | -- | 5.95 | -- | -- | -- |
Perspective Therapeutics Inc | -1.87m | -49.02m | 892.07m | 116.00 | -- | 2.62 | -- | -- | -1.39 | -1.75 | -0.0437 | 5.06 | -0.0074 | -- | -- | -16,086.21 | -19.37 | -- | -20.14 | -- | -- | -- | -- | -- | -- | -- | 0.005 | -- | -- | -- | -- | -- | -- | -- |
MiMedx Group Inc | 340.46m | 89.67m | 899.94m | 895.00 | 12.27 | 5.35 | 9.17 | 2.64 | 0.4996 | 0.4622 | 2.08 | 1.15 | 1.67 | 2.70 | 6.69 | 380,402.30 | 48.16 | -4.14 | 60.79 | -5.90 | 83.41 | 83.61 | 28.76 | -2.70 | 3.22 | 13.06 | 0.1028 | -- | 20.03 | -2.19 | 310.29 | -- | -26.47 | -- |
Immunome Inc | 10.78m | -262.59m | 900.22m | 55.00 | -- | 3.54 | -- | 83.48 | -5.64 | -5.64 | 0.2591 | 4.23 | 0.0639 | -- | -- | 196,072.70 | -155.54 | -94.54 | -193.54 | -112.66 | -- | -- | -2,435.02 | -1,403.15 | -- | -- | 0.00 | -- | -- | -- | -184.68 | -- | 29.52 | -- |
Zymeworks Inc | 62.71m | -112.51m | 930.01m | 290.00 | -- | 2.30 | -- | 14.83 | -1.52 | -1.52 | 0.8531 | 5.69 | 0.1122 | -- | 1.55 | 230,533.10 | -20.13 | -22.58 | -23.21 | -26.90 | -- | -- | -179.42 | -91.17 | -- | -- | 0.00008 | -- | -81.57 | 7.47 | -195.44 | -- | 3.58 | -- |
Nuvation Bio Inc | 1.44m | -510.72m | 937.38m | 167.00 | -- | 2.39 | -- | 653.23 | -2.11 | -2.11 | 0.0064 | 2.43 | 0.0023 | -- | 0.4216 | 28,137.26 | -82.63 | -16.27 | -87.18 | -16.65 | 6.13 | -- | -35,590.24 | -- | -- | -- | 0.0214 | -- | -- | -- | 27.25 | -- | -- | -- |
Sana Biotechnology Inc | 0.00 | -244.90m | 945.48m | 328.00 | -- | 2.78 | -- | -- | -1.15 | -1.15 | 0.00 | 1.53 | 0.00 | -- | -- | 0.00 | -36.94 | -38.99 | -42.11 | -42.70 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.11 | -- | 112.71 | -- |
IGM Biosciences Inc | 2.91m | -220.40m | 958.59m | 204.00 | -- | 7.82 | -- | 329.30 | -3.67 | -3.67 | 0.0485 | 2.07 | 0.0071 | -- | -- | 12,995.54 | -53.94 | -44.66 | -59.96 | -48.20 | -- | -- | -7,571.35 | -23,668.96 | -- | -- | 0.00 | -- | 99.25 | -- | -11.45 | -- | 73.48 | -- |
Aurinia Pharmaceuticals Inc | 207.11m | -50.35m | 1.03bn | 300.00 | -- | 2.82 | -- | 4.97 | -0.3508 | -0.3508 | 1.44 | 2.55 | 0.3862 | 0.8006 | 9.20 | 690,350.00 | -9.39 | -25.97 | -10.78 | -28.24 | 86.08 | -- | -24.31 | -137.64 | 4.82 | -- | 0.1778 | -- | 30.95 | 227.90 | 27.88 | -- | 57.11 | -- |
Holder | Shares | % Held |
---|---|---|
Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 27.74m | 11.22% |
EcoR1 Capital, LLCas of 31 Mar 2024 | 19.21m | 7.77% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 10.47m | 4.24% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 7.42m | 3.00% |
Geode Capital Management LLCas of 30 Jun 2024 | 3.83m | 1.55% |
Abrams Capital Management LPas of 30 Jun 2024 | 3.81m | 1.54% |
Tang Capital Management LLCas of 31 Mar 2024 | 3.55m | 1.44% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 3.04m | 1.23% |
Redmile Group LLCas of 31 Mar 2024 | 3.03m | 1.23% |
Aisling Capital Management LPas of 30 Jun 2024 | 2.54m | 1.03% |